Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual Meeting Mar 15, 2023
Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update Feb 14, 2023
Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) Dec 15, 2022
Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022 Dec 1, 2022
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer Nov 28, 2022
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting Nov 18, 2022
